Quick Answer
MIRA PHARMACEUTICALS, INC. reported Cash and Equivalents of $6.35 million for fiscal year 2025.
MIRA PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.35M | +124.0% |
| 2024 | $2.83M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.64M | — | +261.6% |
| June 30, 2025 | $730.5K | — | -39.4% |
| March 31, 2025 | $1.21M | — | -57.4% |
| December 31, 2024 | $2.83M | — | — |
- MIRA PHARMACEUTICALS, INC. showed an increase of +124.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, MIRA PHARMACEUTICALS, INC.’s cash and equivalents has grown by 124.0% (from $2.83 million to $6.35 million).
- The most recent figure is from MIRA PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: